Gyre Therapeutics (GYRE) stock
Breakaway doesn't score GYRE. It is too thinly traded for a fair Quality Score.
Follow GYRE's news. Pro members can get an alert when Gyre Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. 3,191 stocks are scored and ranked, every 15 seconds while the market is open. Pro members see it live.
What's next for GYRE, and how long its cash lasts
Next step the company has named
Cash runway
$57.3M in cash
Dilution on the horizon
- Shelf registration (S-3, filed Nov 14, 2024)
- At-the-market share sales program (424B5, filed Nov 27, 2024)
Insiders
Chief Operating Officer Weiguo Ye sold 11,000 shares on Jun 18. 8 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
- In 15 days
NRXPNRX Pharmaceuticals
NRXPPreservative-free ketamine
- In 27 days
CAPRCapricor Therapeutics
CAPRDeramiocel
- In 27 days
SVRASavara
SVRAMolgramostim
GYRE's latest filings
Why GYRE isn't scored
The Quality Score reads US-listed stocks worth $50M or more that trade at $1 or more and 300,000 shares or $10M a day. GYRE trades about 129,000 shares a day. A stock that clears every mark is scored from the next weekly rebuild.
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.